Consolidation Treatment with Y90-Ibritumomab Tiuxetan after R-Chop Induction in High-Risk Patients with Follicular Lymphoma (FL) (GOTEL-FL1LC): A Multicentric, Prospective Study

ABSTRACT Relapse is the main cause of therapeutic failure in FL, which makes it necessary to investigate strategies that aim to eradicate minimal residual disease. This is why we set out to evaluate the role of consolidation with Y90-Ibritumomab Tiuxetan (RIT) in high-risk FL patients. As we possessed data making us suspect that prior treatment with Rituximab could reduce the efficacy of RIT, we designed a study with RIT after 4 cycles of CHOP-R and 2 CHOP, but without R. Material and Patients Between April 2008 and April 2010, 30 patients were included in this trial: 17 male (56.7%) and 13 female (43.3%). Their median age was 54.8 (range, 34-76). 20 (69%) patients had ECOG 0. There were no delays or reductions in RIT doses. Results The objective rate of clinical response was 92.1% (CR + CRi + PR), [CI 95%: 83-100%]. Of the 18 patients who presented with partial remission to the induction treatment, 11 (61.1%) had complete CR or remission after the consolidation treatment. There was only one exitus, due to H1N1 viral pneumonia. The most important G 3/4 toxicity was hematological, with 46% thrombopenia and 56% neutropenia. None of the patients in the trial died because of Lymphoma. With median follow-up of 26 months (12-37), the means for disease-free survival or overall survival were not reached. Conclusion The induction procedure with 4 CHOP-R + 2 CHOP prior to consolidation with RIT gives good response rates and RIT improves CR. This combination is safe and shows a high activity in both, induction and consolidation procedures. Disclosure All authors have declared no conflicts of interest.